Clinical proteomics for deveolpment of novel therapy of malignant pleural mesothelioma
Project/Area Number |
18K08174
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Review Section |
Basic Section 53030:Respiratory medicine-related
|
Research Institution | Meijo University (2019-2020) Nagoya University (2018) |
Principal Investigator |
|
Project Period (FY) |
2018-04-01 – 2021-03-31
|
Project Status |
Completed (Fiscal Year 2020)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | 悪性胸膜中皮腫 / プロテオミクス / がん遺伝子 / 分子標的治療 / 分子標的薬 |
Outline of Final Research Achievements |
Malignant pulmonary mesothelioma is a form of tumor that develops from the protective lining that covers the lung and usually caused by exposure to asbestos. We identified that CKAP4 is up-regulated in malignant pleural mesothelioma and further analyses revealed detailed molecular mechanism of CKAP4 which regulates phosphorylation of eIF2α. We also investigated molecular function of OSF2, of which we found high expression in malignant pleural mesothelioma, and identified cluster of phosphorylated proteins regulated by OSF2.
|
Academic Significance and Societal Importance of the Research Achievements |
本研究の成果は、今後30年以上持続的な増加が見込まれているにも関わらず、有効な標準的治療法が確立されておらず、また新たな診断法・治療法の創出につながる有望な標的分子に関する知見も乏しい悪性胸膜中皮腫を対象とした独自性の高い新規分子治療法開発の基盤となり、この様な現状を打破するものと期待される。
|
Report
(4 results)
Research Products
(5 results)
-
[Journal Article] CERS6 required for cell migration and metastasis in lung cancer.2020
Author(s)
Suzuki M, Cao K, Kato S, Mizutani N, Tanaka K, Arima C, Tai MC, Nakatani N, Yanagisawa K, Takeuchi T, Shi H, Mizutani Y, Niimi A, Taniguchi T, Fukui T, Yokoi K, Wakahara K, Hasegawa Y, Mizutani Y, Iwaki S, Fujii S, Satou A, Tamiya-Koizumi K, Murate T, Kyogashima M, Tomida S, Takahashi T.
-
Journal Title
J Cell Mol Med.
Volume: 24
Issue: 20
Pages: 11949-11959
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
[Journal Article] Divergent lncRNA MYMLR regulates MYC by eliciting DNA looping and promoter-enhancer interaction2019
Author(s)
Kajino T, Shimamura T, Gong S, Yanagisawa K, Ida L, Nakatochi M, Griesing S, Shimada Y, Kano K, Suzuki M, Miyano S
-
Journal Title
EMBO J
Volume: 38
Issue: 17
Pages: 1-13
DOI
Related Report
Peer Reviewed / Open Access
-
[Presentation] An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201)2020
Author(s)
Tetsunari Hase, Kiyoshi Yanagisawa, Asuki Fukatsu, Tomoki Kimura, Eiji Kojima, Takashi Abe, Kazuyoshi Imaizumi, Yoshitsugu Horio, Tetsuya Oguri, Masashi Yamamoto, Tomohiko Ogasawara, Yasuteru Sugino, Masahiro Morise, Masahiro Nakatochi, Masahiko Ando, Masashi Kondo, Hideo Saka, Hiroshi Saito, Yoshinori Hasegawa
Organizer
2020 ASCO Annual Meeting(Chicago, USA)
Related Report
Int'l Joint Research